Germany’s G-BA Finds No Added Benefit For CTI’s Pixuvri, Exposing Price
This article was originally published in The Pink Sheet Daily
Executive Summary
Germany’s G-BA lets through Cell Therapeutics’ Pixuvri for aggressive B-cell non-Hodgkin's lymphoma but finds no added benefit over existing therapies, meaning its price could come under pressure.